Eli Lilly and Company (LLY)
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thursday.
Another Surging Pharma Stock to Watch Right Now
Pharmaceutical concern Eli Lilly And Co (NYSE:LLY ) is charging 7.2% higher to trade at $821.20 this afternoon.
Drug-Pricing Deals And Discounted Bets: Why LLY Stock Is A Core Pick In Our Top 10
Eli Lilly stock (NYSE: LLY) surged 5% yesterday, initially driven by news of a Pfizer deal with the White House to lower drug prices in exchange for tariff immunity. Following this, reports surfaced that the broader pharmaceutical companies are in active discussions with the administration regarding discounted drugs.
Eli Lilly in negotiations with Trump administration for the next pharma deal
CNBC's Eamon Javers reports on news regarding the White House.
Is Lilly (LLY) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Eli Lilly and Company (NYSE:LLY ) Bernstein 2nd Annual Global Healthcare Conference September 25, 2025 8:00 AM EDT Company Participants Lucas Montarce - Executive VP & CFO Mike Czapar - Director of Investor Relations Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
Eli Lilly's boss calls UK the 'worst' European country for drug prices
Eli Lilly Chief Executive Dave Ricks said Britain was "probably the worst country in Europe" for drug prices in an interview with the Financial Times, intensifying pressure on the government to improve market conditions for drugmakers.
Eli Lilly to Build $6.5 Billion Ingredient-Manufacturing Facility in Texas
The planned site, which will be used to manufacture the company's first oral weight-loss drug, is expected to be operational within five years.
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
Lilly's Mounjaro helps improve blood sugar control in children in late-stage trial
Eli Lilly's Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight, according to trial results presented at a medical meeting on Wednesday.
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?
Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.
Why the Market Dipped But Eli Lilly (LLY) Gained Today
Eli Lilly (LLY) concluded the recent trading session at $763.57, signifying a +2.06% move from its prior day's close.
